References
- Aronoff SC, Jacobs MR, Johenning S, Yamabe S. Comparative activities of the 0-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother 1984; 26: 580–2.
- Appelbam PC, Jacobs MR, Spangler SK, Yamabe S. Comparative activity of 0-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with 13-lactams against 0-lactamase-producing anaerobes. Antimicrob Agents Chemother 1986; 30: 789–91.
- Jacobs MR, Aronoff SC, Johenning S, Yamabe S. Comparative activities of 0-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with extended-spec-trum penicillins against ticarcillin-resistant Enterobacteriaceae and Pseudomonas. J Antimicrob Chemother 1986; 18: 177–84.
- Moosdeen F, Williams JD, Yamabe S. Antibacterial characteristics of YTR 830, a sulfone 0-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother 1988; 32: 925–7.
- Livermore DM, Seetulsingh P. Susceptibility of Escherichia coli isolated with TEM-1 0-lactamase to combina-tions of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin. J Antimicrob Chemother 1991; 27: 761–7.
- Higashitani F, Mituhashi S. In vitro and in vivo antibac-terial activities of tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 1-25.
- Miyake Y, Miyazaki S, Tsuji A, Kaneko Y, Yamaguchi K, Goto S. In vitro and in vivo antimicrobial activities of tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 34-50.
- Nishino T, Nishida K, Komoto A, Otsuki M. In vitro and in vivo antibacterial activities of tazobactam-piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 73-101.
- Kuck NA, Petersen PJ, Weiss WJ, Testa RT. In vitro and in vivo efficacy of YTR-830H and piperacillin combina-tions versus 0-lactamase-producing bacteria. J Chemother 1989; 1: 155–61.
- Kumazawa J, Matsumoto T, Kumamoto Y, et al. A comparative study of tazobactam/piperacillin (TAZ/PIPC) vs piperacillin (PIPC) for treatment of complicated urinary tract infections. Nishinihon J Urol 1995; 57: 360–83.
- Kumazawa J, Matsumoto T, Kumamoto Y, et al. A comparative study of tazobactam/piperacillin (TAZ/PIPC) and sulbactam/cefoperazone (SBT/CPZ) for the treatment of complicated urinary tract infections. Nishinihon J Urol 1995; 57: 339–59.
- Sanders WE Jr, Sanders CC. Piperacillin/tazobactam : A critical review of the evolving clinical literature. Chin Infect Dis 1996; 22: 107–23.
- Higashitani F, Mitsuhashi S. In vitro and in vivo effica-cy of tazobactam and piperacillin combination and their most effective combination ratio. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 26-33.
- Thabaut A, Meyran M. Activite in vitro de l'association piperacillin-tazobactam sur 224 souches de Pseudomonas aeruginosa en fonction de la production de 0-lactamase. Pathol Biol 1991; 39: 361–6.
- Uji T, Higashitani F, Nishida K, Hyodo A, Unemi N. Therapeutic efficacy of tazobactam/piperacillin in experimen-tal urinary tract infections with 0-lactamase-producing bacte-ria in mice. Chemotherapy (Tokyo) 1994; 42: 1247-53.
- Miyake Y, Nishida K, Higashitani F, Uji T, Hyodo A, Ishida N, Unemi N. In vivo antibacterial activity of tazobac-tam/piperacillin. Chemotherapy (Tokyo) 1994; 42 (suppl 2): 156-63.
- Yokota T. Current status of beta-lactamase production by clinical isolates: studies in 432 hospitals. Chemotherapy (Tokyo) 1991; 39: 941–952.